William Blair analyst Myles Minter has maintained their bullish stance on OVID stock, giving a Buy rating on April 9.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Myles Minter has given his Buy rating due to a combination of factors, beginning with the differentiated science underpinning Ovid’s KCC2 platform, which targets neural circuit hyperexcitability across several severe neuropsychiatric conditions with limited treatment innovation. He views KCC2 as a compelling, neuron-specific “master switch” target that could enable best-in-class therapies for disorders such as Parkinson’s disease psychosis, Lewy body dementia, and acute schizophrenia psychosis.
Minter also highlights that Ovid’s lead oral KCC2 activator, OV4071, is entering Phase I with a robust EEG and ERP biomarker strategy designed to efficiently validate the mechanism before moving into indication-focused trials planned for 2027. Combined with a cash runway extending into 2029, he believes the company can generate multiple clinical readouts, and despite clinical risk typical of early-stage assets, Ovid is well positioned to emerge as the leading direct KCC2 modulator, supporting upside potential in the shares.
In another report released on April 9, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.